EASL 2020: hepatitis C
International EASL Current
EASL recommendations on treatment of hepatitis C: Final update of the series
European Association for the Study of the Liver. J Hepatol. 2020;73:1170–1218
DOI 10.1016/j.jhep.2020.08.018 · Summary checked against the source: 2026-11
EASL called this the final update of the series: with pangenotypic DAAs, treatment is now simple. Grades: evidence A–C with strength 1 (strong) or 2 (weak), written A1, B2 and so on. Pages are from J Hepatol 2020;73:1170–1218.
At a glance
- Diagnose with anti-HCV antibody, then HCV RNA (or core antigen) to confirm viraemia; reflex testing shortens the path to care. [A1 · p. 1173–1174]
- Treat everyone with HCV infection without delay, naive or experienced, recent or chronic. [A1 · p. 1175]
- Stage the liver non-invasively (elastography, APRI, FIB-4): cirrhosis changes the regimen and means lifelong HCC surveillance. [A1 · p. 1177]
- Pangenotypic regimens, no genotyping needed: sofosbuvir/velpatasvir 12 weeks or glecaprevir/pibrentasvir 8 weeks. [B1 · p. 1188]
- Decompensated cirrhosis (Child B/C): no protease inhibitors. Sofosbuvir/velpatasvir + weight-based ribavirin for 12 weeks. [A1 · p. 1191]
- After SVR with cirrhosis: ultrasound every 6 months for HCC, indefinitely. [A1 · p. 1175]
Diagnosis and work-up
- Suspected chronic HCV: anti-HCV antibody (EIA) first, then HCV RNA (sensitive assay, LLOD ≤15 IU/mL) or core antigen. [A1 · p. 1173]
- Recent infection: antibody plus RNA or core antigen. Antibody-positive, RNA-negative: retest RNA at 12 and 24 weeks to confirm clearance. [A1 · p. 1173]
- Dried blood spots work for antibody and RNA, not for core antigen. [A1, B1 · p. 1174]
- Before treatment: confirm viraemia; assess fibrosis; test for HBV (HBsAg, anti-HBc) and HIV, and HAV immunity; vaccinate against HAV and HBV if not immune; check renal function, alcohol, drug interactions and extrahepatic manifestations. [A1 · p. 1176–1177]
- Genotype isn't needed with pangenotypic regimens, but is still useful where available. No baseline resistance testing. [A1 · p. 1178]
- Don't use non-invasive tests to re-stage fibrosis after treatment. [B1 · p. 1177]
Treatment regimens
| Regimen | Dose |
|---|---|
| Sofosbuvir/velpatasvir | 400/100 mg, 1 tablet daily |
| Glecaprevir/pibrentasvir | 300/120 mg (3 tablets) daily with food |
| Sofosbuvir/velpatasvir/voxilaprevir | 400/100/100 mg, 1 tablet daily with food |
Adapted from EASL 2020 [A1 · p. 1187]
Simplified treatment (no genotype)
| Patient | Sofosbuvir/velpatasvir | Glecaprevir/pibrentasvir |
|---|---|---|
| No cirrhosis, treatment-naive or experienced | 12 weeks | 8 weeks |
| Compensated cirrhosis, treatment-naive | 12 weeks | 8 weeks |
| Compensated cirrhosis, treatment-experienced | 12 weeks | 12 weeks |
SVR testing can be omitted after simplified treatment if adherent, except with ongoing risk of reinfection (test SVR at 12 weeks and then yearly). If fibrosis stage is unknown, use 12 weeks for every regimen. Adapted from EASL 2020 Table 6A and recommendations [B1 · p. 1187–1188]
Genotype 3 with compensated cirrhosis (if genotyped): sofosbuvir/velpatasvir plus weight-based ribavirin, or sofosbuvir/velpatasvir/voxilaprevir, for 12 weeks; or glecaprevir/pibrentasvir 8–12 weeks (16 weeks if treatment-experienced). With NS5A testing, ribavirin or voxilaprevir only if Y93H is present. [B1 · p. 1189–1190]
Where these aren't available: generic sofosbuvir + daclatasvir is safe, effective and affordable. [A1 · p. 1188]
Decompensated cirrhosis
Grade A1 [p. 1191]
- Treat in experienced centres with access to liver transplantation, with close monitoring.
- Protease inhibitors (glecaprevir, voxilaprevir, grazoprevir) are contraindicated in Child–Pugh B/C cirrhosis and in Child A with previous decompensation.
- Sofosbuvir/velpatasvir + ribavirin (1,000 mg if <75 kg, 1,200 mg if ≥75 kg) for 12 weeks; start ribavirin at 600 mg if needed. Can't take ribavirin: sofosbuvir/velpatasvir for 24 weeks.
- MELD <18–20: treat before transplant. MELD ≥18–20: transplant first and treat afterwards (unless the wait exceeds 6 months). [A1, B1 · p. 1191]
Special groups
| Group | Recommendation |
|---|---|
| HIV co-infection | Same regimens as HCV mono-infection; check ART interactions (A1) |
| HBV co-infection | Watch for HBV reactivation; NA prophylaxis per HBV guidance |
| HCC | Curative resection or ablation first, then DAAs; 6-monthly ultrasound indefinitely after SVR (A1) |
| Transplant recipients | Treat all post-transplant recurrence; sofosbuvir/velpatasvir 12 weeks needs no immunosuppressant changes (A1, B1) |
| Pregnancy | Not recommended without safety data; case by case only (C2). Breastfeeding is fine unless nipples are cracked or bleeding (B1) |
| Children of infected mothers | Test from 18 months (A1) |
| People who inject drugs | Test routinely; treat everyone, including on opioid substitution (no methadone or buprenorphine dose change); annual RNA after SVR if risk continues (A1) |
Adapted from EASL 2020 [p. 1182–1199]
Clinical pearls
- Anti-HCV positive ≠ active infection: confirm with HCV RNA.
- Pangenotypic: SOF/VEL 12 weeks or G/P 8 weeks. SOF/VEL/VOX for DAA failures.
- No protease inhibitors in decompensated cirrhosis.
- Amiodarone + sofosbuvir: risk of severe bradycardia.
- SVR12 = undetectable RNA 12 weeks after treatment = cure; reinfection is still possible.
Classes and levels of evidence
How EASL 2020 grades its recommendations. Adapted from EASL 2020 grading table [p. 1171]. Hover over any class or level cited on this page to see what it means.
| Class | Meaning | Wording used |
|---|---|---|
| LoE 1 | Systematic review of RCTs or n-of-1 trials (highest level) | |
| LoE 2 | Individual RCT, or observational study with dramatic effect | |
| LoE 3 | Non-randomised controlled cohort or follow-up study | |
| LoE 4 | Case series, case-control or historically controlled studies | |
| LoE 5 | Mechanism-based reasoning or expert opinion | |
| A1 | High-quality evidence (further research very unlikely to change confidence); strong recommendation | |
| A2 | High-quality evidence; weak recommendation | |
| B1 | Moderate-quality evidence (further research may change the estimate); strong recommendation | |
| B2 | Moderate-quality evidence; weak recommendation | |
| C1 | Low-quality evidence (any estimate of effect is uncertain); strong recommendation | |
| C2 | Low-quality evidence; weak recommendation |
| Level | Meaning |
|---|---|
| Strong recommendation | Wording: shall, should, is recommended (or should not). Based on evidence, consistency, risk–benefit, patient preference, ethics and feasibility |
| Weak or open recommendation | Wording: can, may, is suggested (or may not) |
Recent EASL guidelines rate evidence with Oxford Centre for Evidence-Based Medicine levels (1 strongest to 5) and grade each recommendation strong ("should", "is recommended") or weak/open ("can", "may", "is suggested"). Each also records the panel's consensus: strong consensus ≥95%, consensus 75–95%. EASL 2020 HCV instead uses evidence A–C with strength 1–2 (written A1, B2 and so on).